Overview
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
Status:
Withdrawn
Withdrawn
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
Phase 2, multi-center, open label extension study to evaluate 2 dose regimens of fostamatinib in approximately 25 subjects. The study will consist of 11 visits over 15 months.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Rigel Pharmaceuticals
Criteria
Inclusion Criteria:- Completed Study C-938788-050, including having received a post-treatment renal biopsy,
and having had a clinically meaningful response (i.e. decreased proteinuria or
improved renal histology)
- Able and willing to give written informed consent
Exclusion Criteria:
- Unresolved Grade 2 or greater toxicity in Study C-935788-050